Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Kontoghiorghes GJ – A major aspect of the improved therapies is the ability of L1 to mobilize and remove excess cardiac iron and reduce congestive cardiac failure, which is the main cause of death in thalassemia patients. Further, new developments include the use of alternating sequential chelation therapies and selected dose protocols with L1, DFO and deferasirox (DFRA) for overcoming toxicity and efficacy complications observed in some patients treated with monotherapies or combination therapies.
Related Articles
Iron Chelation Therapy for Patients with Myelodysplastic Syndrome
Hemoglobin, 10/23/09
Relevance Score: 81%
Uses and Limitations of Serum Ferritin, Magnetic Resonance Imaging T2 and T2* in the Diagnosis of Iron Overload and in the Ferrikinetics of Normalization of the Iron Stores in Thalassemia Using the International Committee on Chelation Deferiprone/Deferoxamine Combination Protocol
Hemoglobin, 10/23/09
Relevance Score: 81%
Understanding Iron Overload:Screening, Monitoring, and Caring for Patients With Transfusion-Dependent Anemias
Clinical Journal of Oncology Nursing, 10/06/09
Relevance Score: 81%
Iron overload and toxicity: the hidden risk of multiple blood transfusions
Vox Sanguinis, 10/06/09
Relevance Score: 80%
Iron chelation therapy in the management of thalassemia: the Asian perspectives
International Journal of Hematology, 11/04/09
Relevance Score: 79%
Today in Anemia/Polycythemia...keeping you current
Receive free subspecialty "5-minute updates" via email
Peripheral arterial tonometry in assessing endothelial dysfunction in pediatric sickle cell disease
Pediatric Hematology and Oncology, 11/25/09
Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature
Pediatric Hematology and Oncology, 11/25/09
Src tyrosine kinase pre-activation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera
Blood, 11/25/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


